Opinion on Genomics, Proteomics and Pharmacogenomics in North America

Published within

« | 1 | 2 | 3 | 4 | » »|

Type Product title / description Pub Price
Expert View
Expert View

A new phase in the breast cancer battle?

Published By Datamonitor
21 Sep 2001
CommentWire
CommentWire

Abbott Laboratories/Vysis: agreement for cancer tests

Published By Datamonitor
09 Apr 2001
CommentWire
CommentWire

Abbott/Millennium: genomics partnership advances

Obesity is a serious public health concern, costing over $100 billion a year in the US alone, and MLN4760 will complement Abbott's metabolic disease program well. It is also the first fruit of a strategic alliance to develop drugs based on genomic research. Such alliances will become increasingly important in the industry over the next few years.

Published By Datamonitor
28 Nov 2001
CommentWire
CommentWire

Abgenix: a new trial for promising cancer drug

Abgenix's drug could have a promising future. If the compound can improve upon the side effect profile of Roche/Genentech's benchmark monoclonal antibody Herceptin (trastuzumab), as well as gaining further indications, it is likely to become a key player within this field of anticancer treatments.

Published By Datamonitor
07 Jan 2002
CommentWire
CommentWire

Bayer/CuraGen: billion-dollar genomics alliance

Published By Datamonitor
19 Jan 2001
CommentWire
CommentWire

Biotechnology: FDA rule changes could boost generics

The FDA's review of current good manufacturing practice (cGMP) seeks to improve standards of drug manufacture. At the same time, the regulations should reduce confusion over biotech-derived drug products. These changes may open the door to greater use of new manufacturing methods and long term, greater opportunities for biogenerics.

Published By Datamonitor
28 Aug 2002
CommentWire
CommentWire

BMS/Celera: drug discovery to get shorter

Hot on the heels of last month's obesity research deal between Merck and deCODE, BMS and Celera have agreed to team up to develop novel cardiovascular and diabetes drugs. Both partnerships are attempts to accelerate the drug discovery process in cardiovascular diseases - increasingly important as the costs of clinical development continue to rise.

Published By Datamonitor
09 Oct 2002
CommentWire
CommentWire

Celera: u-turn on gene database

Celera will now focus on drug discovery, following in the footsteps of Millennium, HGS and Incyte. In the short term, it will be dependent on license payments from existing customers and from Applied Biosystems for revenues. Its long-term success, however, will be dependent on using its genomics and proteomics resources to produce successful drugs.

Published By Datamonitor
23 Apr 2002
Expert View
Expert View

D-day for diabetes drugmakers

Spanish researchers could be on the brink of curing type 1 diabetes. While this breakthrough is undoubtedly good news for patients, drugmakers could lose out, as the market vanishes before their eyes. But this could not be their biggest threat: anti-obesity drugs could stop people developing diabetes at all - is this the end for diabetes drugs?

Published By Datamonitor
17 May 2002
Expert View
Expert View

Free to partner: life after the license ends

Published By Datamonitor
17 Aug 2001

« | 1 | 2 | 3 | 4 | » »|

No help is available.